The Main Points
- Johnson & Johnson raised its 2026 guidance after posting a positive second quarter, joining insurers UnitedHealth and Elevance in an upbeat week for healthcare earnings.
- The company's CEO pointed to a clearer "line of sight" toward double-digit growth for the roughly $100 billion business.
- J&J has drawn notable attention from members of Congress, several of whom have disclosed large purchases of the stock in recent months.
- The healthcare sector broadly has seen a wave of positive earnings surprises this quarter after a difficult stretch in prior years.
- Investors will be watching whether the raised guidance holds up as the back half of the year unfolds.